with COVID-19 . 02 / 24 / 2022 , page 322-339 . https :// www . covid19treatmentguidelines . nih . gov / therapies / antithrombotic-therapy /.
5 . Cushman , M . Epidemiology and Risk Factors for Venous Thrombosis . Semin Hematol . 2007 April ; 44 ( 2 ): 62 – 69 . https :// www . ncbi . nlm . nih . gov / pmc / articles / PMC2020806 / pdf / nihms21418 . pdf .
6 . Center for Disease Control and Prevention . Division of Blood Disorders , National Center on Birth Defects and Developmental Disabilities , Centers for Disease Control and Prevention February 5 , 2018 . Data and Statistics on Venous Thromboembolism . Doi : https :// www . cdc . gov / ncbddd / dvt / data . html .
7 . Ahmed I , Majeed A , Powell R . Heparin induced thrombocytopenia : diagnosis and management update . Postgrad Med J . 2007 ; 83 ( 983 ): 575-582 . Doi : 10.1136 / pgmj . 2007.059188 .
8 . Cuker A , Tseng EK , Nieuwlaat R , et al . American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 : January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients . Blood Advances . Published online May 3 , 2022 : bloodadvances . 2022007561 . doi : 10.1182 / bloodadvances . 2022007561 .
9 . Rentsch CT , Beckman JA , Tomlinson L , et al . Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States : cohort study . BMJ . 2021 ; 372 : n311 . Doi : https :// www . ncbi . nlm . nih . gov / pubmed / 33574135 .
10 . ATTACC Investigators , ACTIV-4a Investigators , REMAP-CAP Investigators , et al . Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19 . N Engl J Med .
2021 ; 385 ( 9 ): 790-802 . Doi : https :// www . ncbi . nlm . nih . gov / pubmed / 34351721 . 2 .
11 . Sholzberg M , Tang GH , Rahhal H , et al . Effectiveness of therapeutic heparin versus prophylactic heparin on death , mechanical ventilation , or intensive care unit admission in moderately ill patients with COVID-19 admitted to hospital : RAPID randomised clinical trial . BMJ . 2021 ; 375 : n2400 . Doi : https :// www . ncbi . nlm . nih . gov / pubmed / 34649864 .
12 . Spyropoulos AC , Goldin M , Giannis D , et al . Efficacy and safety of therapeuticdose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19 : the HEP-COVID randomized clinical trial . JAMA Intern Med . 2021 ; 181 ( 12 ): 1612- 1620 . Doi : https :// www . ncbi . nlm . nih . gov / pubmed / 34617959 .
West Virginia Medical Journal • March 2024 • 23